Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.